Recent developments raise the bar for cost-effectiveness of the combination of Yervoy/Opdivo
Opdivo is a PD-1–blocking antibody that so far has gained a label in 11 broad oncology indications in the US. Credit: Evgeniy Kalinovskiy/Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more